A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.

Tara L LinLaura F NewellRobert K StuartLaura C MichaelisEric RubensteinHelen S PentikisTimothy CallahanDonna AlvarezBarry D LiboironLawrence D MayerQi WangKamalika BanerjeeArthur C Louie

Published in: Cancer chemotherapy and pharmacology (2019)

Clinicaltrials.gov identifier: NCT02238925.

Keyphrases

open label
left ventricular
double blind
placebo controlled
clinical trial
heart failure